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Abstract

THE ROLE OF SEVERAL KINASES IN MICE TOLERANT TO
t,.9 -TETRAHYDROCANNABINOL.

Matthew C. Lee
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University,

1 999

Director: Sandra P. Welch, Ph.D., Department of Pharmacology and Toxicology

It has been suggested that the CB 1 G-protein-coupled receptor is internalized
following agonist binding and activation of the second messenger pathways. The process
of desensitization and resensitization is intimately involved with receptor internalization.
Phosphorylation alters tolerance to cannabinoids thus contributing to tolerance.

It is

proposed that phosphorylation enhances the down-regulation of the CB 1 receptor. These
findings led us to look at which kinase(s) may be involved in cannabinoid tolerance. We
therefore hypothesize that by preventing phosphorylation of the CB 1 receptor, we may
reverse tolerance. We evaluated our hypothesis by testing the role of several kinases in
tolerance:

protein kinase A (PKA), protein kinase C (PKC), protein kinase G (PKG),

Beta Adrenergic Receptor Kinase ( � -ARK), Phosphatidylinositol 3-kinase (PI3K) and the
src family tyrosine kinase. We also looked at cAMP and cGMP analogs.

We evaluated

PKA using KT5720, a PKA inhibitor; PKC using bisindolylmaleimide I, HCI (bis), a
PKC inhibitor; PKG using KT5823, a PKG inhibitor;

� -ARK

using Low molecular

x

weight heparin (LMWH), a �-ARK i nhibitor; PI3K using LY294002, a PI3K i nhibitor
and PP I a src family tyrosi ne kinase inhibitor. The cAMP analog was dibutyryl-cAMP
and the cGMP analog was dibutyryl-cGMP. ICR mice were rendered tolerant to 1'/
tetrahydrocannabinol (�9-THC) by administering injections of 20mg/kg �9-THC s.c.
every 1 2 hours for 6.5 days. The mice were subsequently challenged 24 hours later with
an ED80 of �9-THC at 20Jlglmouse (i.t.). Antinociception was measured by the tail-flick
test, %MPE ' s and EDsO's were calculated. The PKG inhibitor, KTs823, showed no
significant change in %MPE.

The �-ARK inhibitor, LMWH , showed no significant

change in the %MPE. The PI3K inhibitor, LY294002, showed no significant change in
the %MPE. Inhibition of PKC, by bis had no effect on tolerance, but at a higher dose
attenuated the antinociceptive effect of �9-THC in non-tolerant mice. PP l , the src family
tyrosine kinase inhibitor, reversed tolerance. KTs720, the PKA inhibitor reversed �9_
THC tolerance.

These data support a role for PKA and tyrosine kinase in

phosphorylation events in THC tolerant mice. (Supported by N IDA grants K02DAOO l 86
and PsODAOs274).

Introduction

Background.

Cannabis is one of the most controversial drugs of our time, even

though it has been used for both recreational and medicinal purposes for centuries. In the
United states, ranking only behind alcohol and tobacco, cannabis is one of the most
commonly abused drugs. The use of Cannabis Sativa, also known as Indian Hemp, dates
back over 1 2,000 years (Abel 1 979). Its uses include that of making clothes and rope by
the ancient Chinese and Greeks. It was cultivated in Jamestown, Virginia for its fiber
early i n American history (Grinspoon and Bakalar 1 993). Medicinally it has long been
used in China, India, the Middle East, South America and South Africa. The earliest
references to its medicinal uses date back to 2700 BC (Grinspoon and Bakalar 1 993).
Uses in ancient China included treatment for constipation, malaria, rheumatic pains and
female disorders.

Around 2000 to 1 400 BC in India the euphoric properties were

discovered, and cannabis was recommended for reducing fevers, producing sleep,
stimulating the appetite, rel ieving headaches and curing venereal diseases (Mechoulam
and Feigenbaum 1 987).
It was not until 1 839 that cannabis was i ntroduced into western medicine. During
this time cannabis was found to be a very safe drug (Snyder 1 97 1 , Lemberger 1 984). In
further experiments Snyder showed that high doses did not kill animals. He noted the
therapeutic effects including anticonvulsant action, analgesia, antianxiety and antiemetic
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properties humans. These reports made cannabis an acceptable form of medicine In
England and other European countries. The medicinal use of cannabis waned in the
United States and Europe at the tum twentieth century, due to the development of
synthetic medicines (Adams and Martin 1 996).
The rising fear of cannabis use in the United states began in the 1 920's, and the
use of cannabis was abolished by the enaction of the Marijuana Tax act in 1 937 (Musto
1987). Marij uana is a Mexican term that refers to cannabis leaves or other crude plant
material. Despite the legal measures in the United States, cannabis was a major drug of
abuse during the 1 960s with the peak use in the late 1 970s and early 1 980s. Since then,
use declined to a low in 1 992, and has seemed to be on the rise since (Johnson et al.
1 995).
Cannabinoids are psychoactive compounds that are secreted as a resin from the
flowering tops and leaves of the Cannabis Sativa, subspecies indica, plant. Cannabinoids
are found in the highest concentration in the flowering tops of the plant, fol lowed by the
leaves. Small amounts of cannabinoids are found in the stem and roots, but none in the
seeds (Adams and Martin 1 996). More than 400 compounds are synthesized by the plant,
more than 60 of which are related to L�?-THC. il9-THC is the prototypical cannabinoid
and major psychoactive component in marijuana. It is rapidly metabolized to I 1 -hydroxy
il9-THC, in vivo. Most of the other cannabinoids are inactive or weakly active (Abood et
al. 1 996). il9-THC is a non-crystalline, waxy-liquid substance at room temperature. The
pharmacological activity of il9-THC is stereoselective, with the (-)-trans isomer having
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6-100 times more potency than the (+)-trans isomer, depending on the pharmacological
test (Dewey et al. 1 984).
The Cannabinoid Receptors.

It was initially thought that due to the lipophilic

nature of /).9_ THC and the central depressant effects, cannabinoids medicated their actions
through the disruption of membrane ordering, similar to the mechanism of general
anesthetics (Paton and Pertwee 1 972; Lawrence and Gill 1 975). Four chemically distinct
subclasses of compounds exist with pharmacological and behavioral similarities to /).9_
THC, including compounds with three rings, such as /).9-THC, bicyclic compounds (CP55940), aminoalkylindoles (Win

55,2 1 2 ) and eicosanoids (anandamide).

The

enantioselectivity of /).9-THC reinforced the notion that some cannabinoid actions may
act through a receptor ( Mechoulam et al. 1 988).

Definitive evidence for a specific

cannabinoid receptor became apparent when it was cloned (Matsuda et al. 1 990). A clone
isolated from a rat brain library had homology with other receptors that interacted with G
proteins in the cell membrane. None of the traditional agonists of G proteins bound to
this receptor clone. An identification breakthrough occurred with the discovery that the
mRNA distribution of the receptor clone paralleled that of the cannabinoid receptor.
Confirmation of the identity of the clone occurred when adenylyl cyclase was inhibited
upon exposure to CP 55,940 and /).9-THC in cells transfected with this clone. Adenylyl
cyclase in non-transfected cells did not respond to cannabinoids. CP 55,940 is a non
classical, bicyclic cannabinoid with a 4-25 times greater potency than /).9-THC. Studies
show that CP 55,940 cross-generalized in rat and monkey drug discrimination, and cross
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tolerance developed between the two compounds (Gold et

al.

1 992, Pert wee et al. 1 993).

The human cannabinoid receptor was subsequently cloned and found to have almost
identical homology to the rat receptor (Gerard et al. 1 99 1 ). The cannabinoid receptor is
l inked to a G; protei n which, when activated by phosphorylation, i nhibits the activity of
adenylyl cyclase ( Howlett and Fleming 1 984). Adenylyl cyclase then cannot catalyze the
conversion of ATP to the second messenger cyclic AMP (cAMP) ( Howlett et al. 1 986).
It has been shown electrophysiologically that cannabinoids inhibit an omega conotoxin
sensitive, high voltage-activated N-type calcium channel (Caufield and Brown 1 992,
Mackie and Hille 1 992). Cannabanoids also have been reported to enhance the low
voltage A-type potassium channels ( Deadwyler et al. 1 993).
There are two cannabinoid receptors, CB 1 which is located primarily in the brain
with the highest concentration in the substantia n igra pars reticula, globus palidus, and
molecular layer of the cerebel lum (Felder et al. 1 993 ) and also to a lesser extent in the
periphery in human peripheral blood lymphocytes (Bouaboula et al. 1 993) and mouse
spleen cells ( Kaminski et al. 1 993); an amino-terminal variant of CB 1 receptor, the CB I A
has also been discovered i n brain and several peripheral tissues (Shire et al. 1 995);
and CB2 which has been found on splenic macrophages (Munro et al. 1 993). The role or
the receptors i n the spleen remains elusive.

Even though the CB 1 and CB2 receptors

only share 40% homology, Ll9-THC and CP 55,940 demonstrate similar binding affinity
for both receptor SUbtypes. It was been demonstrated by Lement et al. ( 1 999) through
studying CB 1 receptor knockout mice that the main pharmacological responses to Ll9_
THC, as well as the addictive properties of cannabinoids, are mostly mediated by the CB I
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receptor. It was also suggested that the CB I receptors are required for the development
of physical dependence or to obtain a complete mani festation of the somatic signs of
opiate withdrawal. S ince cannabinoids are highly lipid soluble they have been reported to
partition into cell membranes and alter the acti vity of a number of membrane-associated
enzymes,

providing

(Makriyannis et al.).

an
In

alternate

non-receptor-mediated

mechanism

of

action

CHO cells transfected and not transfected with the CB I receptor,

cannabinoid agonist-activated arachidonic acid release and an increase in i ntracellular
calcium, as well as an inhibition of arachidonic acid uptake, suggest a CB I receptor
independent mode of action (Felder et al. 1992).

The receptor-independent actions

require higher concentrations of agonist to mediate their effects where as the receptor
dependent actions only require nanomolar concentrations of agonist (Felder et al. 1994).
Cannabinoid receptor signaling.

The

CB I

and

CB2

receptors

heterotrimeric G-protei n coupled receptors of the inhibitory subtype, composed of
and y subunits. Upon a ligand binding to the receptor, affinity of the
increases and affinity for GDP decreases, so the

a

a

are
a,

�

subunit for GTP

subunit is able to bind and hydrolyze

GTP. Also the binding of GTP decreases the affinity for the �y subunit, which then
disassociates from the

a

subunit (Childers and Deadwyler 1996). The

a

subunit acts by

inhibiting adenylyl cyclase, which then decreases the amount of cAMP which results in
an i ncrease potassium "A" current (Childers and Deadwyler 1996).

CB I and CB2

stimulation induces the inhibition of adenylate cyclase and the activation of MAPK
(Rinaldi-Carmona et al . 1998).

CB I activation has recently been shown to induce

6
immediate-early gene expression such as Krox 24 through a cAMP-independent pathway
( Bouaboula et al. 1 995) This central cannabinoid receptor mediated effect was blocked
by the CB l receptor antagonist S R 1 4 1 7 1 6A (Rinaldi-Carmona et al. 1 996). Since Krox
24 induction is receptor-mediated, but cAMP-independent there must be another

mechanism of CB 1 receptor-mediated effects besides through cAMP.

From the

observation of two independent signaling pathways, several conclusions have emerged:
MAPK activation is mediated through the G�y subunit and adenylate cyclase responses
are mediated through the Go.i subunit (Rinaldi-Carmona et al. 1 998). The tyrosine kinase
inhibitor, herbimyci n A, has been shown to inhibit the induction of Krox 24, suggesting
that a protein TK may be involved in the Gi stimulation of the gene expre sion
(Bouaboula et al.

1 995).

MAPKs, which become tyrosine phosphorylated in

cannabinoid-treated cells, can also be blocked by TK inhibitors, again suggesting that TK
may play a role in CB I receptor-mediated effects (Bouaboula et al. 1 995).
MAPKs can be activated in response to both GPCR or receptor-tyrosine
kinase (RTK) stimulation.

Insulin receptors belong to the RTK family, and their

stimulation by insulin has been shown to activate MAPKs in CHO cells (Bouaboula et al.
1 997).

S R 1 4 1 7 1 6A completely i nhibited insulin-activated MAPK in CHO cells

transfected with the CB 1 receptor, giving rise to the fact that CB 1 activation is required
for insulin activation of MAPK (Bouaboula et al. 1 997).

This effect could not be

extended to other RTKs ( Bouaboula et al. 1 997). It has also been reported that activation
of PI-3K upstream to the MAPKs is required for PTX-sensitive activation of MAPK by
GPCR (Bouaboula et al. 1 997).

Wortmannin, a PI-3K inhibitor, which is an early

7
intermediate of the G�r mediated MAPK signaling pathway, inhibitor resulted In
significant inhibition of both CP-55,940 and insul in-mediated MAPK activation
(Bouaboula et a1. 1 997). In contrast to the classical EGF receptor paradigm, stimulation
of the MAPK pathway by the IGF I RTK also requires the participation of G�r subunits
derived from PTX-sensitive G proteins. Similar to the GPCR pathway, the IGF signal
can be blocked by either PTX or by an inhibitor of G�r subunit-mediated signaling
( Luttrell et at. 1 995). Thus upstream to Ras there is a convergence or common pathway
of the IGF class of RTK with the GPCR signaling pathway.
There have been other systems of cannabinoid receptor signal transduction
pathways proposed. Some studies show that cannabinoids might activate the inositol
phospholipid pathway. This pathway involves the receptor activating a G protein that in
tum activates phospholipase C.

Phospholipase C cleaves phosphatidylinositol-

bisphosphate (PIP2) into inositol-triphosophate ( IP3)and diacylglycerol (DAG).

DAG

activates PKC, and IP3 triggers calcium release from cellular stores. (Chaudry et at.
1 988). Other studies show no effect on phospholipase C activity, and the generation of
IP3 (Felder et at. 1 992).
An abundance of evidence is available that shows cannabinoids have effects on
the biophysical properties of l ipid bilayers and biological membranes. Specifically, the
psychoactive

cannabinoids,

�9-THC

and

I I _OH_�9-THC,

decrease

the

brain

synaptosomal membrane lipid ordering, while the cannabinoids lacking psychoactive
properties (cannabidiol and cannabinol) do not decrease ordering. This may play a part in
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the mechanism of cannabinoids non-receptor mediated effects, including AA release,
increase in intracellular calcium, and inhibition of AA uptake. It is thought the AA
release may be due in part to inhibition of free fatty acid reacylation. It is possible PLA2
is being activated while simultaneously acyl-transferase is being inhibited. PLA2 and AA
release have been shown to depend on an increase in intracellular calcium levels (Felder
et al. 1 992).
Endogenous Ligands.

The first endogenous ligand for the cannabinoid receptor

anandamide ( ANA) was isolated in 1 992 by Devane et. al. It has a greater affinity for the
CB I receptor than the CB2. It has both similarities and dissimilarities to the classic
cannabinoids. Similarities exist in the interaction with a Gi protein, i nhibition of adenyly1
cyclase and modulation of c-AMP levels in cells (Felder et al. 1 993, Vogel et al. 1 993)
and inhibition of N-type calcium channels (Felder et al. 1 993, Mackie et al. 1 993). ANA
is 4 to 20 times less potent than /19_THC and has a shorter duration of action (Smith et al.
1 994). ANA is structurally dissimilar to /19-THC and it also differs from the classic
cannabinoids in that it is only a partial agonist at the N-type calcium channels, whereas
the cannabinoids are full agonists. ANA appears to display binding and functional
properties similar to previously studied cannabinoid agonist, including the ability to
induce both receptor mediated and non-receptor mediated signaling (Felder et al . 1 993).
Anandamide produced similar pharmacological effects to THC, such as antinociception,
catalepsy, hypomotility and hypothermia, (Fride and Mechoularn 1 993). ANA has also
been shown to be cross tolerant to /19_THC (Pertwee et al. 1 993; Welch et al. 1 995). It is
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i nteresting to note that t, -THC, CP-55,940 and WIN 55,2 1 2-2 affected memory i n rats
where anandamide and cannabidiol did not (Lichtman et al. 1 995). Is this due to sUbtypes
of receptors with different specificities or

i nteraction with NMDA receptors?

The

answers to these questions remain unanswered.
The Cannabinoid Receptor Antagonist and Inverse Agonist.

The antagonist

SR I 4 1 7 1 6A, has a high affinity for the CB l receptor, but not the CB2 receptor (RinaldiCarmona et. al. 1 994). In vitro, it antagonized both cannabinoid-induced inhibition of
adenylyl cyclase activity in rat brain membranes and mouse vas deferens contractions; in
vivo it antagonized behavioral effects of cannabinoid agonists (Rinaldi-Carmona et al.

1 994). S R 14 1 7 1 6A also antagonized the discriminative stimulus effects of both t,9 -THC
in rats and rhesus monkeys (Wiley et al. 1 995) and CP 55,940 in rats (Wiley et al. 1 995).
It has also been demonstrated that SR 1 4 1 7 1 6A not only functions as an antagonist of
cannabinoid mediated effects, but also an inverse agonist (Bouaboula et al. 1 997). The
inverse agonist property was shown through two different signaling pathways, G[lymediated MAPK and Gia-mediated AC responses. S R 1 4 1 7 1 6A reversed the increase in
MAPK activation through the G[ly pathway.
responses through the Gia pathway.

In

SR 1 4 1 7 1 6A also prevented the AC

cells transfected with CB l receptors, S R 1 4 1 7 1 6A

will block insulin stimulated MAPK induction, but i n wild type cells S R I 4 1 7 1 6A had no
effect on i nsulin activated MAPK ( Bouaboula et al. 1 997). This effect seems only to be
related to the PTX-sensitive RTKs including the insulin and IGF 1 receptors, not other
RTKs.
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General Effects o f Ll9.THC. The effects of THC are due to its direct cellular actions on

peripheraJ tissues, and due to its high lipophilicity it is able to cross the blood brain
barriers and cause CNS affects. Behavioral effects are characterized at low doses as a
mixture of depressant and stimulatory effects and at higher doses as predominantly CNS
depression (Dewey (986). The depressant affects of cannabinoids produce hyperreflexia.
Cannabinoids generally cause a reduction in spontaneous locomotor activity (Little et al.
(988) and a decrease in response rates with different reinforcement schedules (Carney et
aJ. (979). Cannabinoids also impair learning and memory in rodents (Carlini et aJ., (970)
and non-human primates (Ferraro and Grilly (973). Other affects that have been shown
in the mouse include hypothermia, immobility (catalepsy) and antinociception (Martin
(985).
Cannabinoid·induced antinociception. Several possible transduction mechanisms for

cannabinoid-induced spinal antinociception have been proposed, including modulation of
adenylate cyclase, calcium, potassium, prostaglandins, and opioids. Cannabinoids have
been shown to i nteract with c-AMP, potassium channels and opioids, but not calcium, in
the production of antinociception in the spinal cord (Welch et al. (995) .

The

administration of pertussis toxin, which prevents G; proteins from interacting with
receptors, significantly attenuates or blocks the antinociception produced by cannabinoids
i.t.

This action suggests the mechanism for antinociception is through the GPCR.

Forskoli n pretreatment, which stimulates adenylyl cyclase, there by increasing cAMP
levels, significantly reduced the antinociception produced by L\9_THC administered i .t.
However the administration of dibutyryl cAMP failed to alter the antinociception
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produced by cannabinoids i.t., but Cl-cAMP a stable analog of cAMP, significantly
blocked the antinociceptive effects produced by i.t. administered cannabinoids. Thus, in
the spinal cord, the antinociceptive effects of the cannabinoids seem to be produced via a
Gi

or Go protei n i n conjunction with the modulation of cAMP because the anti nociceptive

effects of i.t. cannabinoids are blocked by pertussis toxin, forskolin and CI-cAMP (Welch
et al. 1 995). The potency of numerous cannabinoids to inhibit cAMP formation in the
neuroblastoma cells was found to correlate to antinociceptive effects of the drugs in vivo
(Howlett et al, 1 986). Various calcium modulators were tested in combination with the
cannabinoids and failed to produce antinociception or alter the antinociception produced
by administration of cannabinoids i.t.

Multiple potassium channel modulators

admin istered i.t. failed to alter cannabinoid-induced antinociception with the exception,
apamin, a blocker of small (low) conductance calcium-gated potassium channels, which
caused a parallel rightward shift in the dose-effect curves of several cannabinoids (Welch
et al. 1 995). The kappa antagonist, nor-BN! (i.t.), and the kappa I receptor antagonist,
naloxone benzoyl hydrazone (Nal-BZH), but not other opioid antagonists, blocks
cannabinoid (i.t.)-induced antinociception. This antinociceptive block does not occur due
to direct interaction with the kappa receptor, because nor-BN! and nal-BZH fail to
displace cannabinoid binding at the cannabinoid receptor. There is evidence to support
an indirect interaction between the kappa receptor and �9-THC in a study in which the
antinociceptive effects of �9-THC are attenuated with antisera to Dynorphin A ( 1 -8) and
Dynorphin A ( 1 - 1 7 ) (Rowen et al. 1 998). These data indicate that i nteraction of �9_ THC
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with the cannabinoid receptor may cause release of endogenous spinal dynorphins or
leucine enkephalin, a metabolite of dynorphin, leading to antinociception. Some possible
points of interaction of the opioids and cannabinoids include the modulation of calcium,
cAMP and potassium flux (Welch et al. 1 994). Data also supports the i nteraction of
cannabinoids with several endogenous compounds that inhibit nociception.

Data

supports the involvement, in addition to opioids, PGE1, catecholamines, and 5-HT
(Adams and Martin 1 996).
Tolerance to Cannabinoids.

Tolerance develops to the phannacological effects of

cannabinoids in a variety of animal species, including pigeons, rodents, dogs, monkeys
and rabbits. Tolerance has occurred to antinociception (Martin 1 985), anticonvulsant
activity (Colasanti et al. 1 982), catalepsy (Pertwee 1 974), depression of locomotor
activity (Karler et al. 1 984), hypothennia (Thompsom et al. 1 974), hypotension
(Birmingham 1 973), corticosteroid release (Miczek and Dihit 1 980), ataxia in dogs
(Martin et al. 1 976) and schedule- controlled behavior (McMillan et al. 1 970). Tolerance
does not develop to all cannabinoid effects, such as ACTH secretion (Dewey et al . 1 970).
Tolerance has also developed to cannabinoid-inhibition of adenylyl cyclase activity (Dill
and Howlett 1 988).

It

is interesting to note that tolerance developed to cannabinoid-

i nduced stimulation of prostaglandin E2 production and arachidonate release (Burstein et
al. 1 985), but as was mentioned earlier the arachidonate release is not receptor-mediated.
The precise mechanism of the development of tolerance is unknown. Changes at the
cannabinoid receptor level fol lowing exposure to cannabinoids for a long period of time
could result in confonnational changes in the receptor which would produce an altered
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receptor structure, to which the ligand could not bind. Receptor internalization is another
possible mechanism of tolerance. With receptor internalization, receptors are removed
into the cytoplasm where they are either degraded or recycled. The number of receptors
on the surface is decreased. Therefore, the binding to the receptor is decreased (Oviedo et
al. 1 993, Rodriquez de Fonseca et al. 1 994). It has been proposed (Rinaldi-Carmona et al.
1 998) that the rapid receptor internalization process is distinct from the slower process of
receptor down-regulation. Evidence has been presented that shows the cannabinoid
receptor is rapidly internalized following binding of an agonist.

The internalization

appears to occur through clathrin coated pits and is rapid and reversible after short
treatment « 1 5 min.), but not after long treatment (>90 min.). Internalization was not
blocked by pretreatment with PTX and/or cholera toxin, suggesting activation of PTX- or
CTX-sensitive G proteins was not required for internalization. This pathway is similar to
the beta2-adrenergic receptor (Mackie 1 998).

There is little evidence that chronic

administration of cannabinoids alters disposition or metabolism of cannabinoids in the
brain or periphery (Oviedo et al. 1 993), suggesting that tolerance is pharmacodynamic in
nature rather than a consequence of reduced bioavailability. In autoradiographic studies it
wa shown that binding to the CB receptor was decreased, with no apparent regional
selectivity, suggesting a lack of involvement of neural circuitry, second messengers, or
other intervening variables that might lead to differential effects. The reductions appear
to be receptor-mediated. In chronically treated animals the changes were the result in loss
of binding capacity (Bmax) rather than a change in affinity ( KD) (Oviedo et al. 1993).
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Figure 1 . Down-regulation of the cannabinoid receptor. When THC or a C B receptor

ligand binds to the cannabinoid receptor, the receptor is thought to be phosphorylated and
rapidly internalized through clathrin-coated pits. Once in the cytosol several processes
may occur: the receptor can be degraded, which would then require protein synthesis for
a new receptor; or it can be dephosphorylated and recycled to the membrane.
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This rules out the theory that there may be a conformational change in the receptor in
chronically treated animals.
It is thought that the desensitization of the CB receptor may be similar to that of
the beta adrenergic receptor ( � -AR). The decreased responsiveness of the � -AR after
stimulation with a near saturating concentration of l igand appears to be caused by rapid
PKA and GRK phosphorylation.

GRK phosphorylation in tum promotes � -arrestin

binding and receptor i nternalization (Seibold et al. 1 998).

In

the following study, we

inhibit � -ARK, with low molecular weight heparin. If � -ARK plays a role in receptor
activation upon ligand binding or role in receptor desensitization, then we may see an
effect upon of acute or chronic affects of t,9 -THC upon inhibition of � -ARK.
There is a bi-directional cross tolerance noted between the kappa opioids and t,9 _
THC which implies a common mechanism of tolerance may underlie both classes of
drugs (Rowen et al. 1 988). Kappa I antisense administration blocks the anti nociceptive
effects of t,9-THC administered i.t. The antinociceptive effects, but not the hypothermic,
hypoactive or cataleptic are blocked by Dynorphin A ( 1 -8) and Dynorphin ( 1 - 1 7) antisera.
Another mechanism of tolerance that must not be discounted is the role of the G protein
subunit, Gi2a, which might be involved in opioid-induced tolerance expression.
Antisense specific for the Gi2a subunit blocks morphine-induced antinociception and to
different degrees also blocks the effects of different mu agonists. Therefore we may
postulate that alterations i n G proteins, or an uncoupling at the receptor, could account for
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cannabinoid-induced tolerance via the interaction o f the cannabinoids with kappa-opioids.
(Rowen et al. 1998).
The Role of Protein Kinase C in Cannabinoid effects.

It has been shown that

cannabinoids increases the phosphorylating activity of brain PKC in vitro (Hillard and
Auchampach 1 994). Activation of PKC attenuates the modulation of N- and P/Q-type
calcium currents and the Kir currents by G-protein coupled receptors. Fast modulation of
all three channels is mediated by direct binding of G-protei n �y subunits to the channel
itself (Zamponi et al. 1 997).

Phosphorylating the CB I receptor with PKC strongly

suppressed the modulation of P/Q type calcium channels and the Kir current by
cannabinoids (Garcia et al. 1 998). Therefore, neurotransmitters coupled to PKC restore
neuronal excitabil ity and synaptic activity reversing the effects of cannabinoids. Since
PKC disrupts actions of cannabinoids by phosphorylating the CB I receptor, we evaluated
the antinociceptive effects PKC in tolerant mice. In a tolerant mouse the cells function as
if no t19-THC is present, basically the cells have compensated and is able to function
normally even though t19-THC is present.

S ince PKC disrupts the actions of

cannabinoids by phosphorylating the receptor, we also evaluated the effects of inhibition
of PKC on acute antinociceptive effects of t19-THC.
MAP Kinase and its Role in Cannabinoid Effects.

In addition to cannabinoid-

induced signal transduction through cAMP accumulation and blockade of N-type calcium
channels, several actions of cannabinoids may result from the increased level of tissue
eicosaniods that occur in humans and animals treated with cannabinoids. Included in
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the e effects are the effect o n time estimation, heart rate acceleration, and the subjective
'high' in humans; catalepsy i nduction in mice; and hypotension in dogs. The ability of
cannabinoids to mobilize arac hidonic acid from cellular phospholipid storage sites by
activation of PLA2 is thought to be the reason for the increase eicosanoid level.
Anandarnide activates the MAP kinase signal transduction pathway i n mouse peritoneal
cells, and can be blocked by pertussis toxin, suggesting the effect is receptor-mediated
(Wartmann et al. 1 995).

PLA2 is activated by the MAP kinase signal transduction

pathway, which then causes and i ncrease in arachidonic acid (Lin et aI. 1 993).
Phosphotidalinositol-3 kinase.

It is unclear how PI3-K activity might contribute to

activation of the MAPK pathway. It is known that PI3-K is an early i ntermediate of the
G�y"mediated

MAPK

signaling

pathway.

It

is

interesting

to

note

that

phosphatidylinositol-3,4,5,-trisphosphate (PIP3) can directly i nteract with SH2 domains
and might contribute to their recruitment.

Partial reduction of SHC tyrosine

phosphorylation following GPCR stimulation was detected upon inhibition of PI3-K
(Daub et aI. 1 997). Therefore, we proposed to block PI3-K and reduce the SHC tyrosine
phosphorylation.

Such inhibition of PI3-K should block MAPK and cPLA2 release

further down the pathway. If this block altered tolerance, then the action of PI3-K, or the
results of activating the �y subunit could play a role in tolerance or antinociception.
MAPK activation and interactions.

MAPKs become activated in response to

growth factors either through RTK or GPCR triggered signals. Transmission of these
signals requires the formation of a complex between the Grb2 adapter protein with the
guanine nucleotide exchange factor Sos, which upon recruitment to the plasma membrane
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allows activation of the small G protei n Ras, resulting i n subsequent activation of the
M APK pathway (Daub et aI, 1 997).

Stimulation of various GPCRs rapidly induce

tyrosine phosphorylation of the adapter protein SHC and SHC-Grb2 complex formation,
steps that couple both GPCRs and RTKs to Ras.

GPCR-mediated activation of the

Ras/MAPK pathway has been reported to i nvolve src function, leading to the idea that
RTKs and Src family kinase might be required to initiate intracellular signaling cascades
(Daub et a1. 1 997). A dominant negative mutant EGFR cell was evaluated and MAPK
activation through a Gi coupled receptor was abolished (Daub et al. 1 997). Give such
data indicating that GPCRs interact with RTKs in i ntracellular signali ng involving
MAPK, we asked how the GPCR cannabinoid receptor and RTKs, interact and affect
intracellular processes.

An increase in SHC tyrosine phosphorylation and MAPK

stimulation through both Gq- and Gj-coupled receptors was reduced greatly upon selective
inhibition of EGFR function (Daub et al 1 997). Using PP l , a potent inhibitor of the src
family of tyrosine kinases, we may be able to inhibit MAPK stimulation. Inhibition of
MAPK is proposed to address the possibility of antinociception or tolerance working
through MAPK.
PP I has been shown to suppress tyrosine phosphorylation of various Src
substrates, which moderately increased EGF-induced EGFR tyrosine phosphorylation,
while GPCR transactivation was i nhibited somewhat.

PP I targets essential signaling

elements upstream of Ras and downstream of the EGFR ( Daub et a1. 1 997). Stimulation
of the CB I receptor with agonist leads to the activation of krox-24 and immediate early
growth related gene. Krox-24 activation, which is blocked by PTX treatment cannot be
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ascribed to known PTX-sensitive G-protei n pathways: adenylate cyclase, PLC and ion
channel modulation. It has been shown, that herbimycin A, a tyrosine kinase inhibitor,
inhibited the induction of krox-24, suggesting a tyrosine kinase may lie on the route
between Gi and krox-24 (Bouaboula 1 995).

They also showed that MAPKs became

tyrosine phosphorylated in cannabinoid-treated cells. Thus we had reason to evaluate
PP 1 in cannabinoid tolerant animals.
With data suggesting that there are at least two, i f not three pathways (ex subunit,

�y subunit, and possibly ion channel modulation) activated by an agonist binding to the
cannabinoid receptor, and several potential kinases which are activated by those
pathways, we evaluated the role of inhibition of kinases down stream from the Gi-protein
cannabinoid receptor. Our aim was to determine if tolerance and/or antinociception was
altered upon kinase inhibition. We were, thus, addressing the fol lowing HYPOTHESIS:

Delta-9 THC induced anti nociceptive tolerance is a function of the altered
phosphorylation state of either the CB I receptor or proteins involved in the signal
transduction of the CB I receptor. Our goal is to address this hypothesis by the use
of inhibitors of candidate kinases using drugs selective for such kinases.

Methods

Animal model of ,l9.THC tolerance. All studies were perfonned on male ICR

mice. The mice were kept on a 1 2hourl l 2hour light/dark cycle and received food and
water ad libitum. In the acute studies mice weighed 1 6 to 25 g, in chronic studies mice
weighed 25 to 34 g upon testing. Mice were rendered tolerant to ,l9-THC over seven
days. They received twice daily s.c. injections of ,l9-THC (20mglkg) for six days and on
day seven they just received the morning dose. On the morning of day 8 mice were
challenged with an ED-80 of ,l9_THe.
Intrathecal (i.t.) injections. I.t. injections were perfonned following the protocol

of Hylden and Wilcox ( 1 983).

U naesthetized mice were injected with 5 ul of drug

between the L5 and L6 area of the spinal cord with a 30-gauge, Y2-inch needle.
The tail nick test.

Mice were tested for antinociception by the tail flick

procedure (0' Amour and Smith 1 94 1 ). Reaction times of 2 to 4 seconds were employed
for the control, while a time of 1 0 seconds was used for the cutoff to prevent tissue
damage.

Antinociception was quantified as the percent maximum possible effect

(%MPE) fonnula:
%MPE

=

100 x [(test - control)/( 1 0 - control)]

20

21
( Harris and Pierson, 1 964). Values were calculated for each mouse, using at least 4 mice
per dose for which mean effect and standard error of the mean (SEM) were calculated for
each dose. At least 3 doses of each test drug or combination of drugs were used to
generated dose-response curves.
Materials.

Doses for all drugs used were determined i n naive animals using the

maximal dose without toxicity. Time points were determined i n naive animals to where
the drug had its peak effect.

1 00% dimethyl sulfoxide was purchased from Sigma

Chemical Company (St. Louis, MO). KT5720 purchased from Calbiochem (La Jolla,
CA) was prepared in 1 00% DMSO and was i njected i.t. at a dose of 2.7llglmouse 1 5
minutes prior to drug or vehicle (i.t.). The tail flick test was then conducted 1 5 minutes
fol lowing the second injection. KT5823 purchased from Calbiochem (La Jolla, CA) was
prepared in 1 00% DMSO and injected i.t. at a dose of 2.5llglmouse 1 5 minutes prior to
drug or vehicle ( i .t.). The tail fl ick test was then conducted 1 5 minutes following the
second injection. Dibutyryl-cAMP ( 1OIlgimouse) and dibutyryl-cGMP (5Ilglmouse) were
purchased from Calbiochem (La Jolla, CA) and were prepared in dH20 and i njected i.t
15 minutes prior to the i.t. injection of drug or vehicle, fifteen minutes later the tail flick
test was conducted. �9-THC obtained from the National Institute of Drug Abuse (NIDA)
and was prepared i n 1 00% DMSO for acute tests, and

I:

I : 1 8 [ I part ethyl alcohol

purchased from Aaper Alcohol and Chemical Company (Shelbyville, KY): I part
emulphor EL-620: 1 8 parts 0.9% normal sali ne purchased from Baxter (Deerfield, II)] for
tolerance studies. LY294002 was purchased from Biomol (Plymouth Meeting, PA) and
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was prepared in 100 % DMSO and injected i.t. IS minutes prior to drug or vehicle, also
injected i.t. the tail flick test was then conducted 1 5 minutes following the second
injection. Bisindolymaleimide I, HCL purchased from Calbiochem ( La Jolla, CA) was
prepared in dH20 and injected i.t. (5Ilg/mouse) and (0.51lg/mouse) I S minutes prior to
drug or vehicle ( i .t.). The tail flick test was then conducted I S minutes following the
second injection. Low molecular weight heparin (LMWH) was purchased from S igma
Chemical Corporation (St. Louis, MO) and was prepared in dH20 and injected i.t.
(30llg/mouse) IS minutes preceding the i.t. injection of drug or vehicle, the tail flick test
was then conducted I S minutes following the second injection. PP I purchased from
Alexis was prepared i n 100 % DMSO and injected i.t. 1 0 minutes prior to the i.t. injection
drug or vehicle, with the administration of the tail fl ick test I S minutes after the second
i.t. injection.
Statistical analysis.

Analysis of variance ( ANOY A) was used to determine

significant differences between control and treatment animal groups followed by
Dunnett's t-test.

These calculations were performed using StatYiew, version 5 1 2+

(BrainPower, Inc. Agoura Hills, CA). P values of less than 0.05 were deemed significant.
Parallelism of the dose-response curves was determined by the methods of Tallarida and
Murray ( 1 987). Potency ratios were determined using the methods of Coluhoun ( 1 997).
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Figure 2. Summary of drugs, actions, times between injections and test performed.
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Results

The i .t. administration of KT5720, a protein kinase A (PKA) i nhibitor, at a dose
of 2.7llglmouse i n 1 00% DMSO vehicle (i.t.) significantly (p<0.05) reversed L'l,9-THC
anti nociceptive tolerance in a dose-dependent manner, as determined by the tail flick test.
There was a leftward shift of the dose response curve. The ED50 in the L'l,9-THC-tolerant
mice was shifted from 79.63 (95% confidence l imits from 62. 1 0 to 1 02. 1 2) to 8.62
Ilglmouse (95% confidence limits from 4.65 to 1 5.99) in the KT5720 treated mice. The
l ines were parallel and had a potency ratio of 8.32 with 95% confidence limits. (Figure 3).
The protei n kinase G (PKG) i nhibitor, KT5823, at a dose of 2.5llglmouse in 1 00%
DMSO vehicle ( i .t.) had no effect on L'l,9-THC antinociceptive tolerance. [2.4 %MPE in
the tolerant mice compared to 6.7% in the tolerant animals treated with KT58. (Figure
4).]
Bisindolylmaleimide I, HCL (bis), a protein kinase C (PKC) inhibitor, at a dose of
0.5llglmouse administered i.t. in water vehicle did not affect the antinociceptive tolerance
in mice. The %MPEs in the tolerant groups treated with bis compared to vehicle treated
were not significantly different (20. 1 ± 1 5 vs. 1 4. 1 ±6.0, respectively) (Figure 5). At an
increased dose of 51lglmouse there was not a significant shift i n the ED50 values of the
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Figure 3. The reversal of �9-THC by a PKA inhibitor ( KT5720). The graph shows a

significant ( * ) leftward shift of the curve representing the tolerant mice treated with
KT5720 compared to the tolerant mice treated with vehicle. The effect of the PKA
i nhibitor on mice tolerant to �9-THC is the reversal of tolerance.
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Figure 4. A PKG inhibitor ( KT5823) does not alter � -THC antinociceptive tolerance.

This is shown by the fact that there was not a significant change in tolerance in mice
treated with KT5823 or vehicle.
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The PKC inhibitor, bis, at a dose of O.5J..lglmouse did not alter .0.9-THC
anti nociceptive tolerance. As can be seen from the graph, there is not a significant
difference between the tolerant groups of mice treated with bis or vehicle.
Figure 5.
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tolerant mice treated with bis compared to tolerant mice treated with vehicle (40.5 with
95% confidence limits of 3 1 .9 to 5 1 .4 vs. 80. 1 with 95% confidence l imits of 49.7 to
1 28.98, respecti vely) ( Figure 6). The lines were not parallel in the tolerant mice and the
potency ratio was 2.04.

Interesting though, in the non-tolerant mice there was an

attenuation of the antinociceptive effect of �9 -THe. There was a significant (p<O.OS )
rightward shift in the dose-response curve.

The EDSO was shifted from 7. 1 (95%

confidence limits from 4.5 to 1 1 .2 ) in the vehicle-treated non-tolerant animal to 26.3
(95% confidence l i mits from 1 5. 5 to 44. 8 ) in the bis treated non-tolerant animal. The
lines on the graph are parallel and the potency ratio is 3 .6.
Low molecular weight heparin ( LMWH), which inhibits beta adrenergic receptor
kinase ( �-ARK), at a dose of 30 Ilg/mouse in water vehicle administered i.t. did not affect
the antinociceptive tolerance in the mice. The %MPE in the tolerant group treated with
LMWH ( S . 2± 1 .8 ) was not significantly different than the vehicle treated tolerant group
( l 4. 1 ±6.0), ( Figure 7 ).
L Y294002, the a phosphatidylinositol-3-kinase inhibitor, administered i.t. in
1 00% DMSO vehicle at a dose of O. l llg/mouse did not significantly alter �9-THC
antinociceptive tolerance in mice, ( Figure 8). The L Y294002-treated tolerant mice had a
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Figure 6. The PKC inhibitor bis, at a dose of 5!J.glmouse attenuated the effects of t/
THC in non-tolerant mice. As can be seen from the graph, there was a significant ( * )
rightward shift o f the curve representing non-tolerant treated mice.
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Figure 7.
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Figure 8. The PI3-K inhibitor, L Y294002, did not significantly affect antinociceptive
tolerance. This can be seen from the graph in that there is not a significant difference
between the L Y294002 and vehicle treated tolerant animals.

%MPE of 9.5±9.5 compared to the tolerant vehicle treated mice who had a %MPE of
2 .4± 1 . 1 .
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We also looked at PP I which is a src family tyrosine kinase. Since the �y subunit
of the cannabinoid receptor interacts with tyrosine kinase to activate MAPK, we wanted
to look at what would happen if this pathway was disrupted.

At a dose of

0.000 I Ilglmouse, in 1 00% DMSO vehicle administered i.t., PP I significantly (p<0.05)
reversed �9-THC anti nociceptive tolerance in mice.

The O.OOO l llgimouse dose was

shown to be inactive (%MPE 3.7±O.8) in the tail flick test in naive mice, but in the non
tolerant group in had a %MPE of 43.7± 1 9.6. The non-tolerant vehicle treated group also
had a high %MPE (45.3± 1 9.2). (Figure 9). At doses of O.OO l llgimouse and higher PP I
shows a variable anti nociceptive affect
The next step was to look at potentiation of tolerance. If PKA inhibition reversed
tolerance, what would happen if a cAMP analog was given? In order to tell whether of
not there was a potentiation, the dose of �9-THC had to be raised to I OOllgimouse to get
around a 50% MPE in the tolerant mice. Dibutyryl cyclic-GMP at 51lglmouse in water
vehicle administered i.t. did not significantly potentiate tolerance, a 35.5±20A %MPE in
the tolerant animals compared with a 45.8±22.5 %MPE in the drug-treated animals
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Figure 9.
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Figure 10. Dibutyryl-cGMP does not enhance .0.9-THC antinociceptive tolerance. The

graph shows no significant change between the dibutyryl-cGMP treated tolerant mice and
the vehicle treated tolerant mice.

(Figure 10).

Dibutyryl cyclic-AMP at a dose of 1 0�g/mouse in water vehicle

administered i .t. also did not potentiate .0.9-THC antinociceptive tolerance, a 54.7± 1 3.8
%MPE in the tolerant ani mals compared to 45.8±22.5 %MPE in the drug treated animals.
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Even though it was not significant dibutyryl-cAMP seemed to attenuate the effects of !:l9 _
THC in the non-tolerant animals (Figure 1 2).

Kinase

Inhibitor

Effect on tolerance

PKA

KT5720

Reversal

PKG

KT5823

No change

PKC

Bisindolylmaleimide I, HCl

No change

PD-K

LY294002

No change

Tyrosine kinase

PP 1

Reversal

� -ARK

Low molecular weight heparin

No change

Figure 1 1.

tolerance.

Summary of the kinases putatively inhibited, inhibitor and the effect on
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Dibutyryl-cAMP does not enhance t.9-THC antinociceptive tolerance_
Although not significant it does appear to attenuate the antinociceptive effects in non
tolerant mice. It can be seen in the graph that enhancement does not occur because there
is no significant change in %MPE in the tolerant animals treated with dibutyryl-cAMP or
vehicle.
Figure 1 2.

Discussion

what role do various

The question I sought to address in these studies was:
kinases play in �9 -THC anti nociceptive tolerance?

We evaluated kinases that were

downstream from the cannabinoid receptor (PKA, PI3-K, TK), that may interact directly
with the receptor (PKA, �-ARK, PKC) and others that act in different pathways (PKC,
PKG). This discussion begins with kinases downstream from the a subunit, then goes to
kinases downstream to the �y subunit, and ends with the "others" group.
When a l igand binds to a GPCR, as the cannabinoid receptor, there is a decreased
affinity between the

a

and �y subunits and they differentiate from one another. In the

acute model of �9-THC exposure the

a

subunit will cause a decrease in adenyl ate cyclase

which then decreases cAMP followed by a decrease in PKA. There is also an associated
opening of low voltage potassium channels leading to an efflux of potassium and a
modulation of calcium channels leading to decreased calcium conductance.
chronically treated �9-THC model downstream from the

a

In the

subunit there is a

compensatory i ncrease in adenylate cyclase, cAMP and PKA. The is no longer a �9-THC
i nduced modulation of potassium and calcium channels.
The intra-thecal administration of the protein kinase A inhibitor KT5720 reversed
the antinociceptive tolerance of �9-THC. This indicates that protein kinase A plays a role
37
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in the mechanism of � -THC anti nociceptive tolerance whether it i s direct or indirect is
yet to be determined. PKA could be responsible for phosphorylating the CB I receptor
upon binding of the ligand to the receptor, this activation could result in a chain of events
one of which the end result is antinociception. PKA also could be increasing potassium
conductance through phosphorylation of the potassium channel, causing the cell to be
hyperpolarized and unable to fire. Other possible roles of PKA in �9-THC mediated
tolerance includes the possibility that PKA is rapidly and continuously phosphorylating
the CB 1 receptor when it is down-regulated into the cytosol in tolerant animals. Our lab
has shown that receptor density does not change in mice tolerant to �9-THC, the downregulated receptors are not being degraded and new receptors are not being synthesized,
or both processes are going at the same rate, the former is more plausible. The receptors
are rapidly internalized upon exposure to cannabinoids (Mackie et al. 1 998). It has been
suggested that the rapid internalization process of the cannabinoid receptor is distinct
from the slower process of receptor down-regulation. As the cell becomes tolerant the
internalization of the receptor may get longer and longer as the cell undergoes
compensation. Once the cell is tolerant there will be an increased production of PKA to
make up for decrease caused by �9-THC. These higher levels of P KA, compared to
initial exposure could be responsible for a continuous phosphorylation of the CB I
receptor while i n the cytosol. This continued phosphorylation might be what keeps the
receptor down-regulated in the cytosol. Upon inhibition of PKA the receptor will no
longer be phosphorylated and could therefore be recycled to the membrane where it will
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be active and capable of binding to the l igand again. If the phosphorylation is not halted,
and the receptor is kept in the cytosol, eventually it will be degraded, requiring mRNA for
new protein synthesis.
PKA could be responsible for the phosphorylation of the N-type calcium channels
and potassium channels giving rise to the hyper-polarized state of a naive cell and
resulting in antinociception. Upon inhibiting PKA in the tolerant animal, the
phosphorylated channels become dephosphorylated and are therefore i nactive again
(potassium conductance is increased and calcium conductance is decreased), giving rise
to the antinociceptive effects of f19-THC. We know, apamin, a blocker of small (low)
conductance calcium-gated potassium channels blocked the antinociceptive effects of i.t.
administered cannabinoids (Welch 1 995). However, i.t. administration of cannabinoids
are not sensitive to calcium modulation and thus may not directly involve calcium
modulation (Welch 1 995). This leads me to believe the spinal mediated antinociception
does not involve calcium channels.
If PKA reverses cannabinoid anti nociceptive tolerance, what would happen if we
gave a cAMP analog? We would think that a cAMP analog would enhance tolerance. In
a non-tolerant cell exposed to cannabinoids cAMP is decreased, but in the presence of
forskolin, which increases cAMP or CI-cAMP, a cAMP analog antinociception is
attenuated (Cook et al . 1 995).

But, i n our case dibutyryl-cAMP did not enhance

tolerance, though it did, but not significantly attenuate antinociception in the non-tolerant
mice. It would be interesting to see what happens to cannabinoid tolerance in forskolin
treated animals or with a different cAMP analog that is more potent.
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Unsure as to whether or not the Goo mediated signaling pathway through cAMP
was responsible for antinociception, we also wanted to look at kinases involved in the
GJ3y-mediated signal i ng pathway. PI-3 kinase and tyrosine kinase work downstream from
the �y subunit of the GPCR, these kinases are generally associated with growth and
differentiation. With the membrane destabilizing activity of cannabinoids and release of
free arachidonic acid they might play a role in antinociception. The first of these being
PI3-K is an enzyme

LY294002, a specific phosphatidylinositol 3-kinase inhibitor.

implicated in growth factor signal transduction by associating with receptor and nonreceptor tyrosi ne kinases (Vlahos et al. 1 994).

PTX-sensitive RTKs and GPCRs

converge or share a common pathway upstream from ras, which leads to the activation of
MAPK. Our goal was to see if by blocking a kinase or kinases in the pathway, would we
affect tolerance.

In

the case of blocking PI-3K tolerance was not affected. However the

blockade of the src family tyrosine kinase reversed tolerance. Was it a true reversal? At
higher doses the inhibitor, PP I is variably antinociceptive.

In

the non-tolerant groups

PP I had a small antinocicepti ve effect as well as the vehicle.
explanation of a reversal of tolerance?

What is a possible

By blocking a tyrosine kinase we may be

inhibiting downstream actions of the �y subunit, that may be necessary to maintain a
tolerant state or we may be bypassing the traditional route of antinociception, the mice are
still tolerant to t.9-THC, but by inhibiting tyrosine kinase i n the presence of t.9-THC
antinociception is the result. Possibly by inhibiting MAPK and/or PLA2 in the tolerant
animal reverses tolerance. We would think, that since PP I reversed tolerance, L Y294002
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would also. Looking at figures 1 3 and 1 4, PI3-K is necessary for ras formation. P13-K is
also necessary to produce PI345P3 which is required for the complex to form.

By

i nhibiting either one of these steps L Y294002 should reverse tolerance if PP 1 is working
through this same path to reverse tolerance, but it doesn't. Two, of the many possible
explanations are: 1 )PP 1 is not working at the complex formation, or LY294002 is not
getting to the site of action. It would be interesting to look at other TK inhibitors or if
tolerance can be enhanced through a tyrosine kinase analog, this would help clarify how
this kinase may be working in tolerance reversal. Further studies need to be conducted
looking the role of the �y subunit and tyrosine kinases and their role in central
cannabinoid effects.
In addition to kinases downstream to the

a

and �y subunits we also looked at

other kinases. � -ARK is known to phosphorylate the � -AR and is a potential candidate
for phosphorylating the cannabinoid receptor so it can be internalized in a clathrin coated
pit and it is thus desensitized. If this were correct, then by blocking � -ARK with LMWH
we could prevent receptor phosphorylation and possibly desensitization or downregulation. Since LMWH was inactive it appears that the cannabinoid receptor is not
phosphorylated by � -ARK and this kinase is not responsible for the desensitization of the
receptor. Another possible kinase that could activate the CB 1 receptor is � -ARK, of the
GRK family of kinases.

� -ARK also known as GRK2, is thought to possibly to be

involved in the desensitization of the beta adrenergic receptor. Mackie et al. in 1 998
noted that the CB I receptor is internalized following a pathway grossly sirilllar to the one
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used by the beta2-adrenergic receptor. Our data indicate that � -ARK does not play a role
in receptor down regulation in mice tolerant to �9 -THC, since LMWH does not affect the
tolerance. If � -ARK plays a role in cannabinoid induced antinociception it is yet to be
determined.
PKG is known to interact with cGMP and nitric oxide. The inhibition of PKG did
not reverse tolerance. The cGMP analog we looked at, dibutyryl-cGMP did not enhance
tolerance.
PKC may act directly on the receptor and/or downstream from the receptor. It has
been shown that cannabinoids i ncrease brain protein kinase C activity in vitro (Hillard
and Auchampach 1 994) . So what happens if we inhibit PKC in tolerant animals? We
showed at two different doses that tolerance to cannabinoids was not affected by
i nhibiting PKC.

It was shown at the higher dose that inhibiting PKC attenuated the

effects of �9-THC in non-tolerant animals.

Hillard et al. in 1 993 showed that

cannabinoids increase the levels of PKC in rat brain and that these i ncreased levels are
responsible for reestablishing neuronal excitability.

Therefore we would expect the

inhibition of PKC to prolong the effects �9-THC, but this is not what we saw.

If

inhibiting PKC attenuates the effects of cannabinoid-induced antinociception, it might be
likely that these increased levels of PKC may be at least partially responsible for
cannabinoid-induced antinociception.
In summary, the data presented in this thesis demonstrates that by inhibiting PKA
and tyrosine kinase �9-THC antinociceptive tolerance can be reversed. It seems likely
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that these two kinases work independent of one another. The other kinases that were
inhibited including: PKG, PKC, PI3-K and � -ARK did not alter tolerance. However, the
higher dose of PKC was shown to attenuate the effects of t.9-THC in the non-tolerant
ffilce.

The cAMP and cGMP analogs had no significant effects on tolerance

enhancement.
Even though a kinase or analog did not affect tolerance we must not discount its
possible effects or assume it does not alter tolerance. It is possible the drug may not reach
the site of action, it is degraded to rapidly to exert i ts affect or inappropriate time points
and doses were chosen, even though attempts were made to optimize both.
A future direction would be to evaluate phosphorylation state of the receptor. If
PKA is responsible for the initial desensitization or maintaining the down-regulated state
of the receptor we would expect to see the receptor in the phosphorylated state in tolerant
animals. We would also expect to see a dephosphorylated receptor in spinal cord tissue
that had been treated with the P KA inhibitor immediately prior to harvest.
In order to produce new and more specific drugs to treat humans, we must first
understand their mechanism of action. The goal of this research was to evaluate the
underlying mechanisms for t.9 -THC antinociceptive tolerance. In an attempt to one day
prevent tolerance development i n clinical situations.
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Figure 1 3.
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goes the other way allowing a complex to be fonned with second messengers down
stream from the receptor tyrosine kinase (RTK), this convergence of pathways is
upstre� from ras : The P1345P3 is also necessary for the complex fonnation. The end
result IS a modulatlOn of phospholipase A2.
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Putative pathway of second messengers and possible places of action on
kinase inhibitors in the il9-THC tolerant model . Downstream from the ex subunit there is
a compensatory increase in AC, cAMP and PKA. Potassium efflux decreases and
calcium conductance increases. Inhibiting PKA and the src TK reverses tolerance. Since
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inhibiting the src TK reverses tolerance it would seem that inhibiting PI3-K would also
reverse tolerance, but it doesn't.
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